Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This project will test whether adalimumab,and/or galactose can safely reduce proteinuria
(abnormal amounts of protein in the urine) and protect kidney function better than standard
treatment for patients with focal segmental glomerulosclerosis (FSGS).
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) The Cleveland Clinic University of Michigan